Sarepta Therapeutics, Inc.

Total Valuation

Sarepta Therapeutics, Inc. carries a market capitalization of 1.98B, placing it among publicly traded companies globally. Its enterprise value stands at 2.16B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Share Statistics

Sarepta Therapeutics, Inc. currently has 105.62M shares outstanding.

Valuation Ratios

Sarepta Therapeutics, Inc. trades at a trailing price-to-earnings ratio of 34.12. The price-to-sales ratio is 0.95, and the price-to-book ratio stands at 1.24.

Enterprise Valuation

On an enterprise value basis, Sarepta Therapeutics, Inc. trades at an EV/EBITDA multiple of 58.04 and an EV/FCF ratio of 9.72. The EV/Sales ratio of 1.09 reflects the premium investors are willing to pay for the company's revenue stream, while the EV/EBIT multiple of 2,560.37 provides insight into valuation relative to core operating earnings.

Financial Position

Sarepta Therapeutics, Inc. maintains a current ratio of 4.42, meaning it holds 4.4x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 68.45, indicating elevated leverage, while an interest coverage ratio of -0.24 demonstrates limited ability to service its debt obligations.

Financial Efficiency

Taxes

Over the trailing twelve months, Sarepta Therapeutics, Inc. has paid 5.81M in income taxes, reflecting an effective tax rate of 3.56.

Stock Price Statistics

Sarepta Therapeutics, Inc.'s stock has declined approximately -7.07221% over the past 52 weeks. The 50-day moving average sits at 17.29, while the 200-day moving average is 19.02.

Income Statement

Over the trailing twelve months, Sarepta Therapeutics, Inc. generated 1.97B in revenue and converted that into -136.72M in net income, yielding earnings per share of -1.26. EBITDA reached -17.53M, while operating income came in at -62.24M.

Balance Sheet

Sarepta Therapeutics, Inc. holds 788.49M in cash and equivalents against 1.05B in total debt, resulting in a net debt position of 276.48M. Total book value stands at 1.53B, with working capital of 1.72B providing operational flexibility.

Cash Flow

Sarepta Therapeutics, Inc. produced 111.01M in operating cash flow over the past twelve months. After subtracting -36.04M in capital expenditures, free cash flow totaled 74.97M - equivalent to 0.72 per share.

Margins

Sarepta Therapeutics, Inc. operates with a gross margin of 59.09, reflecting its pricing power and cost economics. The operating margin of -3.15 and net profit margin of -6.93 provide insight into operational efficiency.

Dividends & Yields

Stock Splits

Sarepta Therapeutics, Inc.'s most recent stock split took place on July 12, 2012 with a 6:1 split ratio.

Scores

Sarepta Therapeutics, Inc. posts an Altman Z-Score of -0.12, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.